Last updated on August 2018

Safety and Tolerability Study in Solid Tumors

Brief description of study

This is an open-label, multicenter, sequential dose-escalation, and expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of andecaliximab (formerly GS-5745) alone and in combination with chemotherapy.

The study consists of 2 parts (Parts A and B). Participants can only qualify for and participate in 1 part.

Part A is a sequential dose escalation to determine the maximum tolerated dose of andecaliximab in participants with advanced solid tumors that are refractory to or intolerant to standard therapy or for which no standard therapy exists. In Part A, participants will receive andecaliximab only. Part A will consist of between 12 to 48 participants.

Part B is a dose expansion to obtain additional safety and tolerability data for andecaliximab in participants with advanced pancreatic adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, esophagogastric adenocarcinoma, colorectal cancer, or breast cancer. In Part B, participants will receive andecaliximab in combination with standard-of-care chemotherapy. Part B will consist of between 115 to 295 participants.

Please note the study is currently only recruiting in the breast cancer cohorts.

Clinical Study Identifier: NCT01803282

Contact Investigators or Research Sites near you

Start Over

Alabama Oncology
Birmingham, AL United States

Michael Gordon, MD

Pinnacle Oncology Hematology
Scottsdale, AZ United States

Ravindranath Patel, MD

Comprehensive Blood and Cancer Center
Bakersfield, CA United States

Alberto Bessudo, MD

San Diego Pacific Oncology and Hematology Associates, Inc.
Encinitas, CA United States

Steven Hager, MD

Cancer Care Associates Of Fresno
Fresno, CA United States

Heinz-Josef Lenz, MD

University of Southern California (USC)
Los Angeles, CA United States

Ari Baron, MD

California Pacific Medical Center
San Francisco, CA United States

Zev Wainberg, MD

UCLA Medical Center
Santa Monica, CA United States

Manish Patel, MD

Florida Cancer Specialists
Sarasota, FL United States

Alexander Starodub, MD

Parkview Research Center
Fort Wayne, IN United States

Daniel Bruetman, MD

Indiana University Health Goshen Center for Cancer Care
Goshen, IN United States

Paula Rosenblatt, MD

University of Maryland Medical Center
Baltimore, MD United States

Haeseong Park, MD

Washington University School of Medicine
Saint Louis, MO United States

Manish Shah, MD

Cornell University
New York, NY United States

Nashat Gabrail, MD

Gabrail Cancer Center Research
Canton, OH United States

Ki Chung, MD

Greenville Health System, Institute for Translational Oncology Research
Greenville, SC United States

Johanna Bendell, MD

Sarah Cannon Research Institute
Nashville, TN United States

Jordan Berlin, MD

Nashville, TN United States

Saad Khan, MD

UT Southwestern
Dallas, TX United States

University of Utah
Salt Lake City, UT United States

Jorge Chaves, MD

Northwest Medical Specialties
Tacoma, WA United States